Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of the Zolpidem Tartrate Sublingual Lozenge in Adult Subjects With Insomnia Characterized by Difficulty Returning to Sleep After Awakening in the Middle-of-the-Night (MOTN).

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of the Zolpidem Tartrate Sublingual Lozenge in Adult Subjects With Insomnia Characterized by Difficulty Returning to Sleep After Awakening in the Middle-of-the-Night (MOTN).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zolpidem (Primary)
  • Indications Sleep maintenance insomnia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 19 Nov 2010 Results presented at the 10th International Forum on Mood and Anxiety Disorders.
    • 16 Jun 2009 Actual initiation date (May 2007), actual end date (Nov 2007) and actual number of patients (295) added as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Results presented at the 23rd Annual Meeting of the Associated Professional Sleep Societies in Seattle, Washington USA, accoridng to Transcept Pharmeuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top